Leo Luznik

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Semin Oncol 39:683-93. 2012
  2. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
  3. ncbi request reprint Nonmyeloablative alternative donor transplants
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Curr Opin Oncol 15:121-6. 2003
  4. ncbi request reprint Finding the best way to train the immune system against lymphoma
    Leo Luznik
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Lymphoma 47:577-9. 2006
  5. pmc High-dose cyclophosphamide for graft-versus-host disease prevention
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Hematol 17:493-9. 2010
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
  7. pmc Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis
    Jennifer A Kanakry
    Division of Hematology, School of Medicine, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:1514-7. 2013
  8. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
  9. pmc Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
    Nadira Durakovic
    Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 109:4564-74. 2007
  10. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013

Research Grants

Detail Information

Publications34

  1. pmc Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Semin Oncol 39:683-93. 2012
    ..This review discusses the history of HLA-haploidentical SCT, recent clinical results, and immunologic mechanisms of action of high-dose PT/Cy for prevention of graft rejection and GVHD...
  2. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  3. ncbi request reprint Nonmyeloablative alternative donor transplants
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Curr Opin Oncol 15:121-6. 2003
    ..Early clinical results suggest that the use of alternative donors is feasible, therefore potentially allowing full extension of the benefits of allografting to the group of patients in highest need...
  4. ncbi request reprint Finding the best way to train the immune system against lymphoma
    Leo Luznik
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Lymphoma 47:577-9. 2006
  5. pmc High-dose cyclophosphamide for graft-versus-host disease prevention
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Hematol 17:493-9. 2010
    ..This strategy has recently been adapted to human transplantation...
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  7. pmc Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis
    Jennifer A Kanakry
    Division of Hematology, School of Medicine, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:1514-7. 2013
    ..No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations. ..
  8. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  9. pmc Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
    Nadira Durakovic
    Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 109:4564-74. 2007
    ....
  10. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013
    ..AlloBMT may be appropriate in first remission in select high-risk cases...
  11. pmc Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies
    Douglas E Gladstone
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD 21287, USA
    Biol Blood Marrow Transplant 19:647-52. 2013
    ....
  12. pmc HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease
    Javier Bolaños-Meade
    Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Blood 120:4285-91. 2012
    ..Graft failure, 43% in haploidentical pairs, remains a major obstacle but may be acceptable in a fraction of patients if the majority can be cured without serious toxicities...
  13. ncbi request reprint Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity
    Nadira Durakovic
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Transplantation 83:631-40. 2007
    ..There are limited data examining the effects of pharmacological immunosuppression on the in vivo fate of donor lymphocyte infusions (DLI)-derived T cells, their function, and their antitumor efficacy...
  14. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  15. pmc Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
    ..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients...
  16. ncbi request reprint Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
    Leo Luznik
    Divisions of Hematopoiesis Immunology and Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 101:1645-52. 2003
    ....
  17. pmc 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 17:754-8. 2011
    ..5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted...
  18. ncbi request reprint Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide
    Christopher G Kanakry
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Sci Transl Med 5:211ra157. 2013
    ..Together, these findings suggest that Treg resistance to Cy through expression of ALDH may contribute to the clinical activity of PTCy in preventing GVHD. ..
  19. pmc Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302
    Javier Bolaños-Meade
    Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 19:481-5. 2013
    ..We found no significant differences in lymphocyte total or subpopulation counts among the 4 treatment arms, and no notable influence on outcomes...
  20. pmc High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:2076-81. 2011
    ..The 5-year EFS and OS for patients with MCL were 39% and 62%, respectively. This low-toxicity therapeutic approach obviates the need for stem cell products and establishes a platform for future therapies...
  21. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  22. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  23. pmc The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells
    Heather J Symons
    Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:499-509. 2008
    ..These events provide the cellular mechanism of the "allogeneic effect" in antitumor immunity. Cy + CD8(-) DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers...
  24. pmc Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
    Vedran Radojcic
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Immunol Immunother 59:137-48. 2010
    ....
  25. ncbi request reprint Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions
    Nadira Durakovic
    Divisions of Hematologic Malignancies and Cancer Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    J Immunol 177:4414-25. 2006
    ....
  26. ncbi request reprint Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation
    Leo Luznik
    Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Control 9:123-37. 2002
    ..Patients with hematologic malignancies in relapse after allogeneic bone marrow transplantation can be treated by infusing leukocytes from the original stem cell donor...
  27. pmc High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 288 Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Immunol Res 47:65-77. 2010
    ..By reducing the morbidity and mortality of alloHSCT, post-transplantation Cy may expand the applications of this therapy to the treatment of autoimmune diseases and non-malignant hematologic disorders such as sickle cell disease...
  28. pmc STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model
    Vedran Radojcic
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 184:764-74. 2010
    ....
  29. pmc Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
    Amy E Dezern
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:1404-9. 2011
    ..Our single-institution study of consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves the long-term outcomes for FLT3/ITD AML...
  30. pmc HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation
    Amer M Zeidan
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 20:314-8. 2014
    ..8 (mean, 22.5; range, .4 to 94) months. At last follow-up, 8 responders were alive in CR; 6 for over a year. HaploDLI for relapse after haploBMT is associated with acceptable toxicities and can result in durable responses...
  31. pmc Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
    Ashley Munchel
    Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Pediatr Rep 3:e15. 2011
    ..These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies...
  32. pmc Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells
    Christopher G Kanakry
    Division of Hematologic Malignancies, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Blood 117:608-17. 2011
    ..Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML...
  33. ncbi request reprint New treatment approaches in acute myeloid leukemia: review of recent clinical studies
    Kelly Norsworthy
    University of Maryland, Department of Medicine, Baltimore, MD 21287 0013, USA
    Rev Recent Clin Trials 7:224-37. 2012
    ..We will review here recent clinical studies that examined novel pharmacologic and immunologic approaches to AML therapy...
  34. ncbi request reprint Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation
    Leo Luznik
    Division of Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 8:131-8. 2002
    ..These data demonstrate that low-dose TBI and posttransplantation Cy cooperate to prevent graft rejection following the transplantation of standard doses of MHC-identical marrow cells...

Research Grants3

  1. Augmenting Antitumor Immunity after Allografting
    Leo Luznik; Fiscal Year: 2009
    ....
  2. Augmenting Antitumor Immunity after Allografting
    Leo Luznik; Fiscal Year: 2010
    ....